Lucid Diagnostics (LUCD) EBT (2020 - 2026)

Lucid Diagnostics (LUCD) has reported EBT for 7 consecutive years, with -$11.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBT fell 163.28% year-over-year to -$11.7 million; the trailing twelve-month figure through Jun 2026 stood at -$52.3 million (up 5.43% YoY), and the FY2025 full-year result was -$58.0 million, down 27.41% from the prior year.
• EBT advanced to -$11.7 million in Q2 2026 per LUCD's latest filing, from -$13.9 million in the prior quarter.
• Across five years, EBT topped out at -$4.4 million in Q2 2025 and bottomed at -$26.9 million in Q1 2025.
• Historically, EBT has averaged -$13.2 million across 5 years, with a median of -$12.3 million in 2022.
• The sharpest annual moves came in 2022 and 2025: EBT tumbled 235.89% in 2022, then surged 59.66% in 2025.
• Over 5 years, EBT stood at -$14.9 million in 2022, then advanced by 27.45% to -$10.8 million in 2023, then dropped by 6.57% to -$11.5 million in 2024, then slumped by 40.94% to -$16.3 million in 2025, then increased by 28.15% to -$11.7 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$11.7 million, -$13.9 million, and -$16.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.